centre Hospitalier de Wallonie Picarde
- Address
- lock Available on a paid plan
Digestive System Diseases and Inflammatory Bowel Disease Research
At centre Hospitalier de Wallonie Picarde in Tournai, clinical research in gastro-enterology focuses strongly on digestive system diseases and immune-mediated bowel conditions. The studies are mainly aimed at improving treatment options for Crohn's disease, ulcerative colitis, and related forms of inflammatory bowel disease.
- Testing new therapies to help control long-term inflammation in ulcerative colitis
- Evaluating treatment strategies for Crohn's disease after surgery to reduce disease return
- Comparing ways to improve clinical outcomes in patients already responding to infliximab
This area of research aims to refine how chronic bowel diseases are managed, with a focus on better symptom control, sustained remission, and improved quality of life.
Immune System Diseases and Eosinophilic Esophagitis Studies
The site is also active in research on immune system diseases, particularly eosinophilic esophagitis, a condition marked by inflammation of the esophagus. These trials are designed to assess whether new treatments can ease swallowing problems and reduce tissue inflammation.
- Studying a potential therapy for eosinophilic esophagitis and related symptoms
- Assessing both symptom relief and longer-term safety in esophageal inflammation
- Exploring better disease control for patients affected by chronic allergic-type inflammation
This research supports the search for more effective and better-tolerated options for people living with persistent inflammatory conditions of the upper digestive tract.
Neoplasms and Breast Cancer Treatment Research
Clinical trial activity at the hospital also includes neoplasm research, with a focus on oestrogen-receptor-positive, HER2-negative breast carcinoma. The goal is to better understand whether treatment approaches can improve survival for older patients at higher risk of relapse.
- Evaluating the benefit of adding chemotherapy to standard treatment in selected patients
- Studying treatment choices for breast cancer in older adults with higher relapse risk
- Supporting more personalized cancer care based on genomic risk
This line of research reflects the site's broader interest in testing therapies that may improve outcomes while helping tailor care to patient-specific risk profiles.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 21 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Janssen Cilag International2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in centre Hospitalier de Wallonie Picarde
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease | Janssen Cilag International | Phase IV | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 21 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Infliximab | 3 | Unknown | 2021-12-21 | 2024-04-29 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.